Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VolitionRx Limited (VNRX) SEC filings page provides direct access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, periodic reports, and registration-related documents. As a NYSE American-listed issuer, VolitionRx uses these filings to report material agreements, capital-raising transactions, governance changes, and other significant events related to its epigenetics and diagnostic testing business.
Recent Forms 8-K describe several key financing arrangements, such as an amended and restated securities purchase agreement with an institutional investor involving a senior secured convertible promissory note and common stock purchase warrant, underwritten public offerings of common stock and warrants, and a registered direct offering of shares and warrants to existing stockholders and insiders. Other 8-K filings detail amendments to the company’s certificate of incorporation to increase authorized common stock, results of stockholder votes at the annual meeting, and announcements of quarterly financial results and business updates.
These filings also outline the terms of VolitionRx’s securities, including conversion prices, warrant exercise prices, ownership limitations, repayment schedules, security interests in company assets, and conditions that constitute events of default. Investors can review how the company structures its capital, secures funding for research and commercialization of its Nu.Q® and related platforms, and manages its obligations to lenders and underwriters.
On Stock Titan, each VolitionRx filing is accompanied by AI-powered summaries that highlight the most important points, such as new financing terms, changes to authorized share capital, or disclosure of financial results. Users can quickly see which filings relate to earnings (often furnished under Item 2.02), which involve material definitive agreements (Item 1.01), and which concern governance or charter amendments (Items 5.02 and 5.03). This structure helps readers navigate lengthy documents and focus on the aspects most relevant to their analysis of VNRX.
VolitionRx Limited furnished an Item 2.02 Form 8-K announcing it issued a press release with financial results and business updates for the quarter ended September 30, 2025. The company also confirmed a conference call on November 14, 2025 at 8:30 a.m. U.S. Eastern Time. The press release is included as Exhibit 99.1 and is incorporated by reference. The information is being furnished, not filed, under the Exchange Act.
VolitionRx Limited (VNRX) filed an amended 8-K to correct a typographical error and detail changes to its October 10, 2025 underwriting terms. The company and Newbridge Securities modified the over-allotment option so it can be exercised for shares, warrants, or any combination.
On November 7, 2025, the underwriter exercised the option for 1,194,000 Option Shares and 1,732,500 Option Warrants at the same public pricing allocation as the offering ($0.51 per share and $0.01 per warrant, less a 7.0% underwriting discount), generating $582,426 in net proceeds to the company after expenses. In connection with this exercise, VolitionRx issued 83,580 underwriter warrants at a $0.63 exercise price, exercisable six months after issuance and expiring five years after the offering’s closing.
VolitionRx (VNRX) filed an amended 8-K to replace Exhibit 1.1 and report an amendment to its underwriting agreement for a recent equity offering. The original deal covered 11,550,000 shares with accompanying warrants at a combined public price of $0.52 per share and warrant, less a 7.0% underwriting commission, and included a 30‑day over‑allotment option for up to 1,732,500 additional shares and accompanying warrants.
The amendment allows the underwriter to exercise the over‑allotment option for shares, warrants, or any combination, rather than only together. Concurrently, the underwriter exercised for 1,194,000 Option Shares and 1,732,500 Option Warrants at the same price terms. The filing states the 1,732,500 Option Warrants are exercisable for up to 83,580 shares. The amended exhibit corrects typographical errors and supersedes the prior version.
VolitionRx Limited amended its underwriting agreement for a recent public offering. The change lets the underwriter exercise the over-allotment option for shares, warrants, or any combination, rather than only as a combined unit.
On November 7, the underwriter exercised this option for 1,194,000 Option Shares and 1,732,500 Option Warrants at the same public pricing used in the offering, allocated as $0.51 per share and $0.01 per warrant, each less a 7.0% underwriting discount. The base offering previously covered 11,550,000 shares with accompanying warrants to purchase up to 11,550,000 shares at a combined public price of $0.52.
VolitionRx Ltd (VNRX) reported an insider tax-withholding transaction. On 11/01/2025, the Chief Medical Officer had 4,588 shares of common stock withheld (code F) at $0.434 per share to satisfy taxes upon settlement of 9,762 restricted stock units awarded in lieu of cash compensation. Following the transaction, the officer beneficially owns 146,568 shares, held directly. The filing notes that no shares were sold by the reporting person or the company in this transaction.
VolitionRx Ltd (VNRX) reported an insider Form 4 reflecting an administrative tax-withholding event. On 11/01/2025, the reporting officer (GC) had 5,647 shares of common stock withheld and canceled at $0.434 per share to satisfy taxes upon settlement of 12,016 restricted stock units awarded in lieu of cash compensation. The filing states no shares were sold by the insider or the company.
Following the transaction, the reporting person beneficially owned 194,084 shares, held directly.
VolitionRx Ltd. (VNRX) reported an insider transaction on a Form 4. On 11/01/2025, Officer and Secretary Rodney Gerard Rootsaert had 3,197 shares of common stock withheld by the company at $0.434 per share (transaction code F) to satisfy tax withholding upon settlement of 7,612 RSUs that were awarded in lieu of cash compensation. After the transaction, he beneficially owns 137,258 shares directly and 1,007,718 shares indirectly through Concord International, Inc. The filing states that no shares were sold in this transaction.
VolitionRx Ltd (VNRX) reported an insider tax-withholding event. On 11/01/2025, Salvatore Thomas Butera, CEO of Volition Veterinary, had 4,648 shares of common stock withheld and cancelled at $0.434 per share to satisfy taxes upon settlement of 16,996 restricted stock units awarded in lieu of cash compensation. The filing states no shares were sold by the insider or the company.
Following the transaction, Mr. Butera beneficially owned 321,803 shares directly, and 99,350 shares are jointly owned with his spouse.
VolitionRx Ltd (VNRX) reported an insider transaction by Chief Commercial Officer Gael Forterre. On 11/01/2025, 1,753 shares of common stock were withheld and cancelled by the company (Transaction Code F) at $0.434 per share to cover taxes upon settlement of 4,864 RSUs awarded in lieu of cash compensation. The filing states no shares were sold in this transaction.
Following the reported activity, Forterre beneficially owned 153,782 shares directly, plus 5,000 shares indirectly via spouse and 32,500 shares indirectly via Armorica Partners, LLC.
VolitionRx Ltd (VNRX) President & CEO Cameron John Reynolds, also a director, reported buying 110,000 common shares at $0.51 each and acquiring 110,000 warrants for $0.01 apiece, in connection with an underwritten public offering that closed on October 14, 2025.
The warrants are exercisable at $0.60 and expire on October 14, 2030. Following these transactions, he directly owns 2,534,847 common shares, with additional indirect holdings of 1,007,718 shares via Concord International, Inc. and 34,076 shares held by his spouse.